A5008051147- Geochemistry and Elemental Analysis
- Geology and Paleoclimatology Research
- Paleontology and Stratigraphy of Fossils
- Radioactive element chemistry and processing
- Geochemistry and Geologic Mapping
- Geological and Geochemical Analysis
- Geological formations and processes
- Glioma Diagnosis and Treatment
- Mycobacterium research and diagnosis
- Marine and coastal ecosystems
- Geological and Geophysical Studies
- Tuberculosis Research and Epidemiology
- Sleep and related disorders
- Marine Biology and Ecology Research
- Hydrocarbon exploration and reservoir analysis
- Isotope Analysis in Ecology
- Nanoplatforms for cancer theranostics
- Obstructive Sleep Apnea Research
- Cancer Mechanisms and Therapy
- Hormonal and reproductive studies
- Cancer Research and Treatments
- Neuroblastoma Research and Treatments
- Bacterial Genetics and Biotechnology
Oklahoma State University
2019-2021
Valley City State University
2021
University of North Carolina at Chapel Hill
2007
The SecA2 protein is part of a specialized export system mycobacteria. We set out to identify proteins exported the bacterial cell envelope by mycobacterial system. By comparing profiles wall and membrane fractions from wild-type DeltasecA2 mutant Mycobacterium smegmatis, we identified Msmeg1712 Msmeg1704 as SecA2-dependent proteins. These are first endogenous M. smegmatis dependent on for export. Both homologous periplasmic sugar-binding other bacteria, both contain functional...
Significance Climate variations are closely related to changes in ocean circulation, and this has important implications for the availability of oxygen deep waters ocean’s CO 2 sequestration capacity. Potentially anoxic conditions have previously been inferred Southern Ocean Pacific, low proposed North Atlantic during glacial cycles. Here, we provide clear evidence that fully occurred eastern South last interval. This is an finding implying circulation was more sluggish advanced stage ice...
Abstract Isocitrate dehydrogenase 1 mutations (mIDH1) occur in ~80% of grade 2/3 gliomas. Vorasidenib (VOR), an oral, brain-penetrant, dual inhibitor mIDH1/2 enzymes, is investigational treatment for mIDH A neoadjuvant perioperative study gliomas suggested VOR renders the tumor immune microenvironment amenable to checkpoint blockade. This (NCT05484622) evaluates safety/tolerability plus pembrolizumab determine recommended combination dose (RCD) (safety lead-in phase), and CD3+ T-cell...
Abstract BACKGROUND Vorasidenib (VOR) is an oral, brain-penetrant dual inhibitor of isocitrate dehydrogenase 1/2 mutant (mIDH1/2) enzymes. VOR being investigated in a phase 3 study residual or recurrent grade 2 non-enhancing gliomas, which interim analysis showed significantly improved progression-free survival and delayed time to next intervention. A prior neoadjuvant perioperative recurrent, 2/3 gliomas that treatment was associated with interferon signal activation increased T-cell...